My laboratory translational research is focused on identifying novel treatment strategies aimed at improving the cure rate of patients with Hodgkin and non-Hodgkin lymphoma. We are interested in developing targeted agents that are less toxic and potentially more effective, and developing mechanism-based combination regimens. Specifically, we are currently examining the potential therapeutic value of targeting Bcl2, PLK4, PRMT5, and ERK proteins in lymphoma. Our goal is to rapidly translate the current scientific discoveries into novel clinical trials. We are also working on identifying biomarkers that may predict response or resistance to a specific therapy, so we can better match patients with treatments that are likely to be beneficial. These research activities are supported by a Lymphoma SPORE grant (Younes, PI) and a Leukemia and Lymphoma Society of America SCOR grant (Younes, PI).
- BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. Derenzini E, Mondello P, Erazo T, Portelinha A, Liu Y, Scallion M, Asgari Z, Philip J, Hilden P, Valli D, Rossi A, Djaballah H, Ouerfelli O, de Stanchina E, Seshan VE, Hendrickson RC, Younes A. Cell Rep. 2018 Aug 21;24(8):2155-2166. doi: 10.1016/j.celrep.2018.07.055. PMID: 30134175
- NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Liu Y, Mondello P, Erazo T, Tannan NB, Asgari Z, de Stanchina E, Nanjangud G, Seshan VE, Wang S, Wendel HG, Younes A. Proc Natl Acad Sci U S A. 2018 Nov 7. pii: 201806928. doi: 10.1073/pnas.1806928115. [Epub ahead of print]. PMID: 30404918